L-Glutamine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
L-Glutamine: From Nutritional Support to Drug-Induced Osteoporosis
One-Sentence Summary
L-Glutamine is a conditionally essential amino acid widely used as a nutritional supplement, particularly for gut mucosal support and metabolic replenishment in critically ill patients. The TxGNN model predicts it may be effective for Drug-Induced Osteoporosis, though 0 clinical trials and 0 publications currently support this specific direction. The high TxGNN score (99.98%) likely reflects knowledge graph proximity between amino acid metabolism and bone metabolism nodes, rather than a direct causal mechanism.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no India market authorization on file) |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known pharmacology, L-Glutamine is the most abundant free amino acid in the body and serves as a key substrate for protein synthesis, nucleotide production, and energy metabolism in rapidly proliferating cells. It also acts as a precursor for glutathione (an important antioxidant) and contributes to collagen synthesis pathways—which are relevant to bone matrix maintenance.
Drug-induced osteoporosis commonly results from long-term use of corticosteroids, anticonvulsants, or other agents that disrupt bone remodeling, reduce calcium absorption, or impair osteoblast function. The theoretical connection to L-Glutamine rests on its role in supporting collagen precursor metabolism and maintaining cellular anabolic balance, which may help counteract drug-driven catabolic effects on bone. However, these are mechanistic extrapolations rather than demonstrated effects.
The TxGNN model’s high prediction score (0.9998) most likely reflects graph-level proximity between amino acid metabolism nodes and bone metabolism pathways in the underlying knowledge graph—not a direct pharmacological causal link. No clinical trials or preclinical studies specifically testing L-Glutamine in drug-induced osteoporosis have been identified. This prediction should be treated as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered for this indication.
Literature Evidence
Currently no related literature available for Drug-Induced Osteoporosis and L-Glutamine.
India Market Information
L-Glutamine currently holds no market authorizations in India. The drug is not marketed domestically, and no license records are on file.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is a complete absence of clinical or preclinical evidence specifically linking L-Glutamine to drug-induced osteoporosis; the TxGNN score is high (99.98%), but this appears to be driven by knowledge graph node proximity rather than mechanistic or empirical evidence. An L5 evidence level does not support advancing this repurposing candidate at this time.
To proceed, the following is needed:
- Preclinical studies (animal models of corticosteroid-induced osteoporosis) testing L-Glutamine supplementation on bone mineral density and collagen matrix
- Mechanistic studies clarifying whether L-Glutamine modulates osteoblast/osteoclast activity under drug-induced conditions
- Retrieval of detailed MOA data from DrugBank (DG002) and official package insert warnings/contraindications from the TFDA (DG001)
- Market authorization pathway assessment for India given current zero-registration status
Note: Among the 10 predicted indications in this Evidence Pack, Dermatitis (Rank 3) presents a more actionable evidence profile (L3, 2 clinical trials, 20 publications, with RCTs demonstrating L-Glutamine’s effect on radiation-induced dermatitis and animal models supporting anti-inflammatory activity via CARD11-mTORC1 pathway). If further investigation is planned, Dermatitis may warrant prioritization over Drug-Induced Osteoporosis.
This report is for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.